Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson’s disease

被引:0
作者
Huimin Chen
Jinping Fang
Fangfei Li
Liyan Gao
Tao Feng
机构
[1] Capital Medical University,Department of Neurology, Center for Neurodegenerative Disease, Beijing Tiantan Hospital
[2] Beijing institute for brain disorders,Parkinson’s Disease Center
[3] China National Clinical Research Center for Neurological Diseases,undefined
来源
Neurological Sciences | 2015年 / 36卷
关键词
Parkinson’s disease; Wearing-off; Levodopa; Safe dosage;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study was to investigate the risk factors of wearing-off phenomenon in Parkinson’s disease (PD) and propose safe dosage of levodopa to reduce wearing-off development based on Chinese cohort. Patients with PD who had taken levodopa (l-dopa) for at least 1 month were recruited. Wearing-off was diagnosed based on validated Chinese version of a patient self-rated 9-question Wearing-Off Questionnaire (WOQ-9) and clinical definition. Eleven variables (gender, disease duration at l-dopa initiation, disease duration at assessment, age at onset, age at assessment, H-Y stage, UPDRS III, l-dopa daily total dosage and dosage adjusted to weight, duration of l-dopa treatment, initial drug recipe) were included in our analysis. Univariate analysis, multivariate logistic regression analysis and decision tree classification model(DTC) were used to detect risk factors of wearing-off. Receiver operating characteristic (ROC) curve and DTC were used to investigate cut-off value of l-dopa to best predict wearing-off. Two hundred and thirty-four patients were investigated in our study, among whom 111 developed wearing-off. Patients with wearing-off tended to receive higher l-dopa dosage and endure longer duration of l-dopa treatment. l-Dopa dosage as 281 mg/day and 4.2 mg/kg/day by ROC, as well as 269 mg/day and 3.2 mg/kg/day by DTC were cut-off values for wearing-off. l-Dopa dosage and duration of l-dopa treatment were related to increased wearing-off development. Cumulative l-dopa dosage and l-dopa daily dosage were better predictive of wearing-off. Inadequate evidence was present for delayed l-dopa initiation. l-Dopa daily dosage no more than 275 mg or 4.2 mg/kg was regarded as safe.
引用
收藏
页码:1217 / 1223
页数:6
相关论文
共 30 条
  • [1] Zhang ZX(2005)Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai Lancet 365 595-597
  • [2] Poewe W(2010)Levodopa in the treatment of Parkinson’s disease: an old drug still going strong Clin Interv Aging 5 229-238
  • [3] Benbir G(2006)A hospital-based study: risk factors in development of motor complications in 555 Parkinson’s patients on levodopa therapy Clin Neurol Neurosurg 108 726-732
  • [4] Ahlskog JE(2001)Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 448-458
  • [5] Muenter MD(2014)The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa Brain 137 2731-2742
  • [6] Cilia R(2013)Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease Mov Disord 28 1064-1071
  • [7] Warren Olanow C(2014)Prevalence of wearing-off and dyskinesia among the patients with Parkinson’s disease on levodopa therapy: a multi-center registry survey in mainland China Translational Neurodegeneration 3 26-1037
  • [8] Chen W(2009)Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson’s disease J Clin Neurosci 16 1034-2305
  • [9] Kum WF(2000)Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study Brain 123 2297-80
  • [10] Schrag A(2007)Risk factors associated with the development of motor complications in Parkinson’s disease. A study in a Chilean population Rev Neurol 45 77-1760